Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

A subset of colorectal cancer (CRC) with a mesenchymal phenotype (CMS4) displays an aggressive disease, with an increased risk of recurrence after surgery, reduced survival, and resistance to standard treatments. It has been shown that the AXL and TGFβ signaling pathways are involved in epithelial-t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Med Oncol
Main Authors: Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thomas, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciaramella, Vincenza, Corte, Carminia della, Barra, Giusi, Selvaggi, Francesco, Franco, Renato, Marino, Federica Zito, Cuomo, Antonio, Morgillo, Floriana, Troiani, Teresa, Sibilia, Maria, Ciardiello, Fortunato, Martinelli, Erika
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2021
Assuntos:
Original Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878213/
https://ncbi.nlm.nih.gov/pubmed/33570712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-021-01464-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares